Resumen de Evaluation of the efficacy and safety of eribulin in the treatment of metastatic breast cancer
Pablo Selvi Sabater, José Carlos Titos Arcos, Angela María Rizo Cerdá, Noemí Manresa Ramón, José Enrique de la Rubia Ortí
Objectives: To study the effectiveness and safety of eribulin treatment in metastatic breast cancer (MBC) in patients who have been treated with at least two lines of treatment that included anthracyclines and taxanes.
Method: Descriptive retrospective analysis including patients who have received eribulin for the treatment of MBC since it became available on the market up to September 2013. The following variables were analysed: gender, age,hormonal and HER-2 receptors, previous lines of treatment, cycles of eribulin received, location of the metastases, response to treatment based on the RECIST criteria and objective rate of response (ORR), progression-free survival (PFS), overall survival (OS) and eribulin-related adverse reactions (AR).
Results: Twenty-six women diagnosed with MBC with a median age of 57 years (range 33-81) were included in the study. 86% were hormone sensitive and 77% were HER-2 negative. The median number of previous lines of treatment was five and the median number of eribulin cycles received was six. The ORR was 26.09% with a median PFS of 137 days (4.6 months) and an OS of 240 days (measured in seven patients). Eribulin-related AR affected 18 patients, with a total of 44 AR seen (6 of grade 3 or 4). Notable among these were: asthenia, gastrointestinal alterations, nervous system alterations, anaemia and dermatological AR.
Conclusions: The effectiveness results obtained in our study are comparable to those from the available studies, with an ORR that was greater than the pivot study and a similar PFS. Regarding safety, eribulin is well tolerated with an AR profile comparable to the published data
